Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoine Meyer

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
Alimentary Pharmacology & Therapeutics|December 31, 2021
Editorial: subcutaneous CT-P13 in Crohn's disease and ulcerative colitis-small change, big consequencesFranck Carbonnel, Antoine Meyer
Alimentary Pharmacology & Therapeutics|April 8, 2025
Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis. Authors' ReplyAntoine Meyer, Aurélien Amiot
Alimentary Pharmacology & Therapeutics|March 4, 2025
Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's ReplyAurelien Amiot, Antoine Meyer, Franck Carbonnel
Arthritis & Rheumatology (Hoboken, N.J.)|August 31, 2021
ReplyEmilie Sbidian, Laëtitia Penso, Antoine Meyer
Alimentary Pharmacology & Therapeutics|December 8, 2022
Editorial: ustekinumab during pregnancy - reassuring but still not enoughAurelien Amiot, Antoine Meyer, Franck Carbonnel
Alimentary Pharmacology & Therapeutics|April 13, 2023
Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisationAntoine Meyer, Aurélien Amiot, Franck Carbonnel
Alimentary Pharmacology & Therapeutics|December 2, 2021
Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factorLaurène Parrot, Catherine Dong, Franck Carbonnel, et al.
Alimentary Pharmacology & Therapeutics|July 14, 2020
Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' replyHadrien Alric, Aurélien Amiot, Franck Carbonnel, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 7, 2023
ReplyAntoine Meyer, Marie-Christine Boutron-Ruault, Franck Carbonnel
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 10, 2026
Risk of lymphoma associated with biologics and immunosuppressants in inflammatory bowel disease patients: a nationwide nested case-control studyAntoine Meyer, Alain Weill, Franck Carbonnel, et al.
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Alimentary Pharmacology & Therapeutics|December 31, 2021
Editorial: subcutaneous CT-P13 in Crohn's disease and ulcerative colitis-small change, big consequencesFranck Carbonnel, Antoine Meyer
Alimentary Pharmacology & Therapeutics|April 8, 2025
Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis. Authors' ReplyAntoine Meyer, Aurélien Amiot
Alimentary Pharmacology & Therapeutics|March 4, 2025
Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's ReplyAurelien Amiot, Antoine Meyer, Franck Carbonnel
Arthritis & Rheumatology (Hoboken, N.J.)|August 31, 2021
ReplyEmilie Sbidian, Laëtitia Penso, Antoine Meyer
Alimentary Pharmacology & Therapeutics|December 8, 2022
Editorial: ustekinumab during pregnancy - reassuring but still not enoughAurelien Amiot, Antoine Meyer, Franck Carbonnel
Alimentary Pharmacology & Therapeutics|April 13, 2023
Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisationAntoine Meyer, Aurélien Amiot, Franck Carbonnel
Alimentary Pharmacology & Therapeutics|December 2, 2021
Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factorLaurène Parrot, Catherine Dong, Franck Carbonnel, et al.
Alimentary Pharmacology & Therapeutics|July 14, 2020
Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' replyHadrien Alric, Aurélien Amiot, Franck Carbonnel, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 7, 2023
ReplyAntoine Meyer, Marie-Christine Boutron-Ruault, Franck Carbonnel
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 10, 2026
Risk of lymphoma associated with biologics and immunosuppressants in inflammatory bowel disease patients: a nationwide nested case-control studyAntoine Meyer, Alain Weill, Franck Carbonnel, et al.
Pageof 7